Real-world study tracks how long men stay on prostate cancer treatments
NCT ID NCT07086651
First seen Dec 08, 2025 · Last updated May 26, 2026 · Updated 20 times
Summary
This study reviewed medical records from cancer clinics to see how long men with metastatic prostate cancer that still responds to hormone therapy take two common drugs, apalutamide and enzalutamide. It included about 1,300 men aged 18 and older who started one of these drugs as their first treatment. The goal was to understand real-world treatment patterns, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer, Inc
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.